Combination therapy efavirenz/emtricitabine/tenofovir disoproxil fumarate associated with hepatic failure

Curr Drug Saf. 2012 Nov 1;7(5):391-3. doi: 10.2174/157488612805076534.

Abstract

A single pill daily fixed dose combination of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) provides a potent and convenient treatment option for HIV/AIDS. The components have been shown to be well tolerated and are effective in randomized controlled trials. A literature search revealed no case of hepatic failure reported with this drug combination. We here in describe the 1st case of acute hepatic failure developing after 3 months of treatment with EFV/FTC/TDF in a 41 year old African American male without pre-existing liver disease or risk factors.

Publication types

  • Case Reports

MeSH terms

  • Adenine / adverse effects
  • Adenine / analogs & derivatives*
  • Adult
  • Deoxycytidine / adverse effects
  • Deoxycytidine / analogs & derivatives*
  • Drug Combinations
  • Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
  • HIV Infections / drug therapy
  • Humans
  • Liver Failure / chemically induced*
  • Male
  • Organophosphonates / adverse effects*
  • Oxazines / adverse effects*
  • Reverse Transcriptase Inhibitors / adverse effects*

Substances

  • Drug Combinations
  • Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
  • Organophosphonates
  • Oxazines
  • Reverse Transcriptase Inhibitors
  • Deoxycytidine
  • Adenine